These findings suggest that treating IDC cell lines with esiRNA targeting several kinases, which are responsible for distinguishing the LumA BC phenotype from the basal BC phenotype30, leads to a reduction in ERα levels. This evidence concerns the gene ESR1 and breast cancer.